Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00143143|
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : July 24, 2006
|Condition or disease||Intervention/treatment||Phase|
|Epilepsies, Partial Epilepsy, Complex Partial||Drug: Pregabalin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pregabalin BID Open-Label Add-On Trial: A Follow-Up Study To Determine Long-Term Safety and Efficacy in Patients With Partial Seizures|
|Study Start Date :||September 2001|
|Study Completion Date :||February 2006|
- Safety assessments are performed at quarterly visits up until the study is closed.
- Seizure frequency is assessed throughout the study until the study is closed.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00143143
Show 46 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|